This healthcare franchise combines a perfect four-quarter earnings beat streak averaging 23.2% positive surprise, 63% revenue growth, a maximum Piotroski financial health score, and a golden-cross technical breakout — one of the highest-quality growth setups in the universe — though the 5.1% upside at the current spot price creates an asymmetry gap that favors waiting for a pullback near the $812.92 entry target.
Thesis pillars
- Exceptional Business Quality→Stable
- Perfect Four Quarter Beat Streak→Stable
- Sixty Three Percent Revenue Growth→Stable
- +2 more pillars — see the Why tab for full reasoning
argenx SE (ARGX) Stock Analysis
Breakout setup · Catalyst-Driven edge
Healthcare · Biotechnology
Wait for pullback to $854.62. At $916.80 the A.R:R is 0.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $854.62 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Thin upside margin: 3.2%; Near 52-week high (3.9% away).
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP),... Read more
Wait for pullback to $854.62. At $916.80 the A.R:R is 0.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $854.62 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Thin upside margin: 3.2%; Near 52-week high (3.9% away). Chart setup: Golden cross, above all MAs, RSI 54, MACD bullish. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 6.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 17d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-07-06Recent Developments — argenx SE
Latest news
- NEWS Argenx SE stock (NL0010832176): Investor conferences and immunology pipeline in focus - AD HOC NEWS — AD HOC NEWS positive
- NEWS ARGENX : RBC reaffirms its Buy rating - marketscreener.com — marketscreener.com neutral
- NEWS Argenx SE stock (NL0010832176): pipeline progress and commercial ramp in focus for Brussels investor - AD HOC NEWS — AD HOC NEWS positive
- NEWS Argenx to Present at Upcoming Investor Conferences - marketscreener.com — marketscreener.com neutral
- NEWS TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity - Investing.com UK — Investing.com UK positive
Generated 2026-07-06T23:11:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $854.62. At $916.80 the A.R:R is 0.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $854.62 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Thin upside margin: 3.2%; Near 52-week high (3.9% away). Chart setup: Golden cross, above all MAs, RSI 54, MACD bullish. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $946.03 (+3.2%), stop $784.58 (−16.9%), A.R:R 0.4:1. Score 6.9/10, moderate confidence.
Take-profit target: $946.03 (+10.6% upside). Target $946.03 (+3.2%), stop $784.58 (−16.9%), A.R:R 0.4:1. Stop-loss: $784.58.
Thin upside margin: 3.2%; Near 52-week high (3.9% away); Expensive valuation.
argenx SE trades at a P/E of 41.7 (forward 25.5). TrendMatrix value score: 3.9/10. Verdict: Buy (Wait for Entry).
25 analysts cover ARGX with a consensus score of 4.2/5. Average price target: $1051.
What does argenx SE do?argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in...
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.